Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: A case report and literature review

Medicine (United States)

Volumn 96, Issue 50, 2017, Pages

  Chen, Jia Hung ^a   Lee, Kang Yun ^a   Hu, Chaur Jong ^a,b   Chung, Chen Chih ^a,b  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Checkpoint inhibitors; Immune related adverse events; Myasthenia gravis; Myositis; Polyneuropathy

Indexed keywords

CHOLINERGIC RECEPTOR ANTIBODY; CREATINE KINASE; CYTOKERATIN 5; CYTOKERATIN 6; CYTOKERATIN 7; IPILIMUMAB; NIVOLUMAB; PREDNISOLONE; PYRIDOSTIGMINE; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CLINICAL ARTICLE; CREATINE KINASE BLOOD LEVEL; DYSPNEA; ELECTROMYOGRAPHY; HUMAN; HUMAN TISSUE; LARYNGOSCOPY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MUSCLE STRENGTH; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; MYOSITIS; NERVE CONDUCTION; NON SMALL CELL LUNG CANCER; POLYNEUROPATHY; PRIORITY JOURNAL; PTOSIS; SQUAMOUS CELL LUNG CARCINOMA; X-RAY COMPUTED TOMOGRAPHY; CHEMICALLY INDUCED; LUNG TUMOR;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; IPILIMUMAB; LUNG NEOPLASMS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; MYOSITIS; POLYNEUROPATHIES;

EID: 85039768013     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000009262     Document Type: Article

References (15)

1. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363: 711-23.
2. Hellmann MD, Rizvi NA, Goldman JW, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol 2017;18: 31-41.
3. Cuzzubbo S, Javeri F, Tissier M, et al. Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer 2017;73: 1-8.
4. Liao B, Shroff S, Kamiya-Matsuoka C, et al. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol 2014;16: 589-93.
5. Johnson DB, Saranga-Perry V, Lavin PJ, et al. Myasthenia gravis induced by ipilimumab in patients with metastatic melanoma. J Clin Oncol 2015;33: e122-4.
6. Lopez D, Calvo A, Fershko A. Myasthenia gravis and rhabdomyolysis in a patient with advanced renal cell cancer treated with nivolumab: A case report and review of the literature. Br J Med Health Res 2015;2: 11-6.
7. Kimura T, Fukushima S, Miyashita A, et al. Myasthenic crisis and polymyositis induced by one dose of nivolumab. Cancer Sci 2016;107: 1055-8.
8. Maeda O, Yokota K, Atsuta N, et al. Nivolumab for the treatment of malignant melanoma in a patient with pre-existing myasthenia gravis. Nagoya J Med Sci 2016;78: 119-22.
9. Sciacca G, Nicoletti A, Rampello L, et al. Benign form of myasthenia gravis after nivolumab treatment. Muscle Nerve 2016;54: 507-9.
10. Shirai T, Sano T, Kamijo F, et al. Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma. Jpn J Clin Oncol 2016;46: 86-8.
11. Polat P, Donofrio PD. Myasthenia gravis induced by nivolumab therapy in a patient with non-small cell lung cancer. Muscle Nerve 2016;54: 507.
12. Chang E, Sabichi AL, Sada YH. Myasthenia gravis after Nivolumab therapy for squamous cell carcinoma of the bladder. J Immunother 2017;40: 114-6.
13. Loochtan AI, Nickolich MS, Hobson-Webb LD. Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer. Muscle Nerve 2015;52: 307-8.
14. Bilen MA, Subudhi SK, Gao J, et al. Acute rhabdomyolysis with severe polymyositis following ipilimumabnivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. J Immunother Cancer 2016;4: 36.
15. Jacob A, Unnikrishnan DC, Mathew A, et al. A case of fatal Guillain-Barre syndrome from anti-PD1 monoclonal antibody use. J Cancer Res Clin Oncol 2016;142: 1869-70.